Invivyd, Inc. announced the presentation of VMS063, a novel monoclonal antibody candidate showing strong antiviral activity against measles virus variants, at IDWeek 2026. VMS063 is designed for both treatment and prevention of measles, addressing a critical gap as there are currently no FDA-approved measles treatments. With measles cases surging in the U.S. in 2026 and millions vulnerable due to immunity gaps, VMS063 could offer a new precision therapy and supplement existing vaccines. Invivyd is scaling up production and aims to begin clinical development in 2027, potentially offering intramuscular or subcutaneous administration options.
Invivyd's new monoclonal antibody candidate VMS063 is presented amid a health sector where 71 of 150 US stocks rose and 67 fell on Pluang today. For readers following health stocks, here is Pluang's market snapshot as of Oct 21, 2026 18:11 WIB: Danaher Corporation (DHR) traded at USD 212.10 with a 5.32% decline and 79% sell order activity, Twist Bioscience Corp (TWST) at USD 137.09 with a 3.93% drop but 100% buy order activity, and Tango Therapeutics Inc. (TNGX) rose 3.76% to USD 26.20 with a typical hold time of 6 days.
The Human Feedback Foundation, supported by RBC, has launched the Agentic AI Design Exchange, a national program aimed at helping Canadian nonprofits design, build, and deploy AI agents responsibly. Funded through RBC's Stronger Nonprofits Program, t...
Satellos Bioscience Inc., a clinical-stage company focused on treatments for degenerative muscle diseases, announced its management will participate in two investor conferences in November: the Guggenheim Healthcare Innovation Conference on Nov 9 in ...
YYForce Inc. has purchased 20 wearable data collection systems to gather real task data from hotel room service at Novotel Singapore. This project aims to record and analyze experienced staff performing tasks like bed-making, towel folding, and clean...
The global digital health and remote patient monitoring market is projected to grow from $26.8 billion in 2025 to $80.8 billion by 2031, at a compound annual growth rate of 20.2%. This growth is driven by increasing demand for chronic disease managem...
The global private credit and alternative lending market, valued at $2.31 trillion in 2026, is expected to grow at a 7.8% CAGR to reach $3.36 trillion by 2031. Recent liquidity pressures in 2025, triggered by bankruptcies and AI sector concerns, caus...
